| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| SC 13D | Filing by person(s) reporting owned shares of common stock in a public company >5% |
Other
|
||
| D |
Other
|
|||
| 3/A | An amendment to a 3 filing. Non-EDGAR filing |
3,4,5
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
